Huasun(SZ:000790) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-22 19:28Core Viewpoint - Chengdu Huasheng Technology Group Co., Ltd. plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., with an initial listing price of RMB 63.7806 million [1][2]. Group 1: Announcement Details - The company held its 23rd meeting of the 13th Board of Directors on August 1, 2025, and the first extraordinary general meeting of shareholders on August 19, 2025, where the proposal for the equity transfer was approved [1]. - The public listing for the transfer commenced on August 21, 2025, and will last until August 27, 2025 [1]. Group 2: Impact of the Transaction - The transaction is subject to uncertainties regarding the counterparties and final transaction price, which may affect the company's operating performance [2]. - The company emphasizes that the transaction will be conducted based on principles of fairness, openness, and justice, adhering to legal and regulatory requirements for information disclosure [2].